• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    CHIEF FINANCIAL OFFICER Rampolla Javier bought $2,981 worth of shares (501 units at $5.95), increasing direct ownership by 1% to 40,745 units (SEC Form 4)

    2/10/25 3:20:55 PM ET
    $SRTS
    Medical/Dental Instruments
    Health Care
    Get the next $SRTS alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Rampolla Javier

    (Last) (First) (Middle)
    851 BROKEN SOUND PARKWAY NW STE 215

    (Street)
    BOCA RATON FL 33487

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Sensus Healthcare, Inc. [ SRTS ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    CHIEF FINANCIAL OFFICER
    3. Date of Earliest Transaction (Month/Day/Year)
    02/10/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 02/10/2025 P 501 A $5.95 40,745 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    /s/ Javier Rampolla 02/10/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $SRTS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SRTS

    DatePrice TargetRatingAnalyst
    1/31/2025$18.00Buy
    Lake Street
    11/15/2024$12.00 → $14.00Buy
    Maxim Group
    3/3/2022$12.00 → $13.00Buy
    HC Wainwright & Co.
    2/14/2022$10.00 → $12.00Buy
    HC Wainwright & Co.
    12/2/2021$9.00 → $10.00Buy
    HC Wainwright & Co.
    11/5/2021$7.00 → $9.00Buy
    HC Wainwright & Co.
    8/6/2021$6.00 → $7.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $SRTS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF FINANCIAL OFFICER Rampolla Javier bought $2,981 worth of shares (501 units at $5.95), increasing direct ownership by 1% to 40,745 units (SEC Form 4)

      4 - Sensus Healthcare, Inc. (0001494891) (Issuer)

      2/10/25 3:20:55 PM ET
      $SRTS
      Medical/Dental Instruments
      Health Care
    • PRESIDENT AND GENERAL COUNSEL Sardano Michael bought $5,950 worth of shares (1,000 units at $5.95), increasing direct ownership by 0.87% to 115,839 units (SEC Form 4)

      4 - Sensus Healthcare, Inc. (0001494891) (Issuer)

      2/10/25 3:16:03 PM ET
      $SRTS
      Medical/Dental Instruments
      Health Care

    $SRTS
    Leadership Updates

    Live Leadership Updates

    See more
    • Sensus Healthcare Celebrates Skin Cancer Awareness Month by Promoting Awareness and Spotlighting its Patient-Friendly, Non-Invasive Treatments

      Innovative SRT-100 Vision (IG-SRT) and SRT Vision Technologies allow dermatologists to treat non-melanoma skin cancer without surgery or patient downtime May is Skin Cancer Awareness Month and Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, is leveraging a wide range of activities to draw attention to the importance of prevention, early detection and treatment of the most common form of cancer that affects millions of people worldwide. Throughout the month of May, Sensus Healthcare is actively promoting skin cancer awareness

      5/1/25 4:30:00 PM ET
      $SRTS
      Medical/Dental Instruments
      Health Care
    • Sensus Healthcare Announces Retirement of Director Samuel O'Rear

      BOCA RATON, Fla., Feb. 01, 2024 (GLOBE NEWSWIRE) --  Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces that Samuel O'Rear will not stand for reelection to the Company's Board of Directors at the Company's 2024 annual meeting of stockholders.  Mr. O'Rear has been a Director of Sensus Healthcare since 2012. As previously announced, on January 11, 2024 the Board of Directors of Sensus Healthcare appointed Michael J. Sardano, President and General Counsel of Sensus Healthcare, as a Director, effective today. "Sam has been inv

      2/1/24 8:00:00 AM ET
      $SRTS
      Medical/Dental Instruments
      Health Care
    • Sensus Healthcare Prepares Organization for Long-term Growth with Three Promotions

      BOCA RATON, Fla, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces the following promotions, all effective immediately: Vice President and General Counsel Michael J. Sardano has been promoted to President and General CounselSales Manager Christopher Machuzak has been promoted to Vice President of Sales for the West CoastSoutheast Regional Sales Manager Jeffrey Starling has been promoted to Vice President of Sales for the East Coast In addition, the Company announces the retirement of Steve Cohen, Executive Vice Pre

      1/31/22 4:05:00 PM ET
      $SRTS
      Medical/Dental Instruments
      Health Care

    $SRTS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Chow Carlton

      3 - Sensus Healthcare, Inc. (0001494891) (Issuer)

      6/10/25 5:33:41 PM ET
      $SRTS
      Medical/Dental Instruments
      Health Care
    • CHIEF FINANCIAL OFFICER Rampolla Javier bought $2,981 worth of shares (501 units at $5.95), increasing direct ownership by 1% to 40,745 units (SEC Form 4)

      4 - Sensus Healthcare, Inc. (0001494891) (Issuer)

      2/10/25 3:20:55 PM ET
      $SRTS
      Medical/Dental Instruments
      Health Care
    • PRESIDENT AND GENERAL COUNSEL Sardano Michael bought $5,950 worth of shares (1,000 units at $5.95), increasing direct ownership by 0.87% to 115,839 units (SEC Form 4)

      4 - Sensus Healthcare, Inc. (0001494891) (Issuer)

      2/10/25 3:16:03 PM ET
      $SRTS
      Medical/Dental Instruments
      Health Care

    $SRTS
    Financials

    Live finance-specific insights

    See more
    • Sensus Healthcare Reports First Quarter 2025 Financial Results

      21 SRT systems shipped during the quarter; revenues of $8.3 million 65% increase in treatment volume from FDAs over preceding quarter Profitability forecast for the next three quarters and for the full year Conference call begins at 4:30 p.m. Eastern time today Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces financial results for the three months ended March 31, 2025. Highlights of the first quarter of 2025 include the following: Revenues were $8.3 million Net loss was $2.6 million, or $(0.16) per share Shi

      5/15/25 4:05:00 PM ET
      $SRTS
      Medical/Dental Instruments
      Health Care
    • Sensus Healthcare to Report First Quarter 2025 Financial Results and Hold Business Update Conference Call on May 15

      Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces the company will report financial results for the first quarter of 2025 on Thursday, May 15, 2025. Management will hold a conference call beginning at 4:30 p.m. Eastern time to review the results, provide a business update and answer questions. Participants are encouraged to pre-register for the conference call using this link to receive a unique dial-in number to bypass the live operator. Participants may pre-register at any time, including up to and after the call sta

      5/1/25 8:00:00 AM ET
      $SRTS
      Medical/Dental Instruments
      Health Care
    • Sensus Healthcare Reports Fourth Quarter and Full Year 2024 Financial Results

      Shipped a record 39 SRT systems during the quarter; revenues of $13.1 million Achieved fifth consecutive quarter of profitability; diluted EPS of $0.09 Conference call begins at 4:30 p.m. Eastern time today Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces financial results for the three and 12 months ended December 31, 2024. Highlights include the following: Revenues were $13.1 million for the fourth quarter and $41.8 million for the year, up 4% and 71% respectively, compared with the prior year Net income

      2/5/25 4:05:00 PM ET
      $SRTS
      Medical/Dental Instruments
      Health Care

    $SRTS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Lake Street initiated coverage on Sensus Healthcare with a new price target

      Lake Street initiated coverage of Sensus Healthcare with a rating of Buy and set a new price target of $18.00

      1/31/25 9:07:11 AM ET
      $SRTS
      Medical/Dental Instruments
      Health Care
    • Maxim Group reiterated coverage on Sensus Healthcare with a new price target

      Maxim Group reiterated coverage of Sensus Healthcare with a rating of Buy and set a new price target of $14.00 from $12.00 previously

      11/15/24 8:09:06 AM ET
      $SRTS
      Medical/Dental Instruments
      Health Care
    • HC Wainwright & Co. reiterated coverage on Sensus Healthcare with a new price target

      HC Wainwright & Co. reiterated coverage of Sensus Healthcare with a rating of Buy and set a new price target of $13.00 from $12.00 previously

      3/3/22 6:32:52 AM ET
      $SRTS
      Medical/Dental Instruments
      Health Care

    $SRTS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Sensus Healthcare Reports First Quarter 2025 Financial Results

      21 SRT systems shipped during the quarter; revenues of $8.3 million 65% increase in treatment volume from FDAs over preceding quarter Profitability forecast for the next three quarters and for the full year Conference call begins at 4:30 p.m. Eastern time today Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces financial results for the three months ended March 31, 2025. Highlights of the first quarter of 2025 include the following: Revenues were $8.3 million Net loss was $2.6 million, or $(0.16) per share Shi

      5/15/25 4:05:00 PM ET
      $SRTS
      Medical/Dental Instruments
      Health Care
    • Sensus Healthcare Celebrates Skin Cancer Awareness Month by Promoting Awareness and Spotlighting its Patient-Friendly, Non-Invasive Treatments

      Innovative SRT-100 Vision (IG-SRT) and SRT Vision Technologies allow dermatologists to treat non-melanoma skin cancer without surgery or patient downtime May is Skin Cancer Awareness Month and Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, is leveraging a wide range of activities to draw attention to the importance of prevention, early detection and treatment of the most common form of cancer that affects millions of people worldwide. Throughout the month of May, Sensus Healthcare is actively promoting skin cancer awareness

      5/1/25 4:30:00 PM ET
      $SRTS
      Medical/Dental Instruments
      Health Care
    • Sensus Healthcare to Report First Quarter 2025 Financial Results and Hold Business Update Conference Call on May 15

      Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces the company will report financial results for the first quarter of 2025 on Thursday, May 15, 2025. Management will hold a conference call beginning at 4:30 p.m. Eastern time to review the results, provide a business update and answer questions. Participants are encouraged to pre-register for the conference call using this link to receive a unique dial-in number to bypass the live operator. Participants may pre-register at any time, including up to and after the call sta

      5/1/25 8:00:00 AM ET
      $SRTS
      Medical/Dental Instruments
      Health Care

    $SRTS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Sensus Healthcare Inc. (Amendment)

      SC 13G/A - Sensus Healthcare, Inc. (0001494891) (Subject)

      2/6/24 12:27:47 PM ET
      $SRTS
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Sensus Healthcare Inc. (Amendment)

      SC 13G/A - Sensus Healthcare, Inc. (0001494891) (Subject)

      2/10/23 11:51:22 AM ET
      $SRTS
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Sensus Healthcare Inc. (Amendment)

      SC 13G/A - Sensus Healthcare, Inc. (0001494891) (Subject)

      2/7/22 8:30:08 AM ET
      $SRTS
      Medical/Dental Instruments
      Health Care

    $SRTS
    SEC Filings

    See more
    • Sensus Healthcare Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Sensus Healthcare, Inc. (0001494891) (Filer)

      6/2/25 4:20:10 PM ET
      $SRTS
      Medical/Dental Instruments
      Health Care
    • SEC Form SD filed by Sensus Healthcare Inc.

      SD - Sensus Healthcare, Inc. (0001494891) (Filer)

      5/30/25 4:05:32 PM ET
      $SRTS
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Sensus Healthcare Inc.

      SCHEDULE 13G/A - Sensus Healthcare, Inc. (0001494891) (Subject)

      5/22/25 4:13:39 PM ET
      $SRTS
      Medical/Dental Instruments
      Health Care